Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China

BACKGROUND: TP53 mutations are common in breast cancer. There is currently no large‐scale cohort study to investigate the TP53 landscape in breast cancer patients from China. The predictive value of TP53 mutations for the efficacy of human epidermal growth factor receptor 2 (HER2)‐targeted therapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Zongbi, Ma, Fei, Rong, Guohua, Guan, Yanfang, Li, Chunxiao, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307233/
https://www.ncbi.nlm.nih.gov/pubmed/32436611
http://dx.doi.org/10.1002/cac2.12032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307233/
https://www.ncbi.nlm.nih.gov/pubmed/32436611
http://dx.doi.org/10.1002/cac2.12032

Ejemplares similares